Andrew B. Ward mostly deals with Virology, Epitope, Antibody, Glycan and Protein structure. His Virology study integrates concerns from other disciplines, such as HIV vaccine, Immunogen, Recombinant DNA and Antigen. His work in the fields of Gp41 overlaps with other areas such as Trimer.
The concepts of his Antibody study are interwoven with issues in Virus, Conserved sequence and Germline. He interconnects Glycosylation and Neutralizing antibody in the investigation of issues within Glycan. His work carried out in the field of Protein structure brings together such families of science as Viral entry, Protein subunit, Binding site and Cell biology.
His scientific interests lie mostly in Virology, Antibody, Epitope, Glycoprotein and Trimer. He has included themes like Monoclonal antibody and Antigen in his Virology study. His studies in Antibody integrate themes in fields like HIV vaccine, Ebolavirus, Immune system and Vaccination.
The Epitope study combines topics in areas such as Immunogen, Recombinant DNA and Glycan. His study in Glycan is interdisciplinary in nature, drawing from both Glycosylation, Peptide sequence, Cell biology, Protein structure and Binding site. His Glycoprotein research is multidisciplinary, incorporating perspectives in Antigenicity, Immunogenicity, Hiv 1 envelope, Computational biology and Viral protein.
Virology, Antibody, Epitope, Glycoprotein and Neutralization are his primary areas of study. Andrew B. Ward mostly deals with Neutralizing antibody in his studies of Virology. His Antibody research incorporates elements of Virus, Immunity and Severe acute respiratory syndrome coronavirus 2.
His Epitope study incorporates themes from Influenza vaccine, Immunogenicity, Influenza A virus, Glycan and Polyclonal antibodies. His Glycan research integrates issues from Glycosylation, Computational biology and Gp41. Borrowing concepts from Trimer, Andrew B. Ward weaves in ideas under Glycoprotein.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Stephen G. Aller;Jodie Yu;Andrew Ward;Yue Weng.
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Jason S. McLellan;Marie Pancera;Chris Carrico;Jason Gorman.
Flexibility in the ABC transporter MsbA: Alternating access with a twist
Andrew Ward;Christopher L. Reyes;Jodie Yu;Christopher B. Roth.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Crystal structure of a soluble cleaved HIV-1 envelope trimer.
Jean-Philippe Julien;Albert Cupo;Devin Sok;Devin Sok;Robyn L. Stanfield;Robyn L. Stanfield.
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Robert Pejchal;Katie J. Doores;Katie J. Doores;Laura M. Walker;Reza Khayat.
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
Rogier W. Sanders;Rogier W. Sanders;Ronald Derking;Albert Cupo;Jean-Philippe Julien.
PLOS Pathogens (2013)
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Dmitry Lyumkis;Jean-Philippe Julien;Natalia de Val;Albert Cupo.
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore.
Rational HIV immunogen design to target specific germline B cell receptors
Joseph Jardine;Jean Philippe Julien;Jean Philippe Julien;Sergey Menis;Takayuki Ota.
Highly Conserved Protective Epitopes on Influenza B Viruses
Cyrille Dreyfus;Nick S. Laursen;Ted Kwaks;David Zuijdgeest.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: